Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP, CFO | April 20, 2022 | April 22, 2022 |
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Director | June 06, 2023 | June 08, 2023 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Horizon Therapeutics Public Ltd Co
Report date April 20, 2022 · Filed April 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,049 |
Ending reported balance
After 2022-04-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-04-20 · Exercise / conversion · Acquired 50,000 · Balance 51,049 Row 2 · 2022-04-20 · Sale · Disposed 28,458 · Balance 22,591 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.79 to $114.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-04-20 · Sale · Disposed 21,542 · Balance 1,049 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.82 to $115.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.14 · Expires 2025-03-22 | Direct | 36,424 |
Reported balance
After 2022-04-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-04-20 · Exercise / conversion · Disposed 50,000 · Balance 36,424 F5: The option is fully vested and exercisable. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy LLC | 66,673 |
Reported balance
Holding disclosure · report date 2022-04-20 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 66,673 F4: The Reporting Person and his spouse share voting power over the securities held by the LLC. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 72,789 |
Reported balance
Holding disclosure · report date 2022-04-20 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 72,789 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.79 to $114.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.82 to $115.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The Reporting Person and his spouse share voting power over the securities held by the LLC.
F5: The option is fully vested and exercisable.
OnKure Therapeutics, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.01 · Expires 2033-06-05 | Direct | 17,500 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,500 · Balance 17,500 F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Sagimet Biosciences Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2036-06-11 | Direct | 39,567 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 39,567 · Balance 39,567 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 4,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012407 · doc4.xml · derivative · entry 5 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,718 Underlying: Ordinary Shares · 4,718 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 1,045 | $87.17 | $91,092.65 |
DisclosureSEC source: 0001209191-21-012407 · doc4.xml · nonDerivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,362 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 2,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012407 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,407 F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 22:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 3,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012407 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 275,151 Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 22:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 3,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012407 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049 Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:01 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionPerformance Restricted Stock Units (PSUs) · Derivative | 5,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004994 · doc4.xml · derivative · entry 5 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,558 Underlying: Ordinary Shares · 5,556 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F2 · derivative.expiration_date: The shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:01 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,462 | $77.43 | $190,632.66 |
DisclosureSEC source: 0001209191-21-004994 · doc4.xml · nonDerivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,143 Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:01 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 5,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004994 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Jan 23, 2021 02:01 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 169,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004994 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 272,057 Read SEC document |
| January 19, 2021 Filed Jan 23, 2021 02:01 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 169,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004994 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049 Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 02:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 14,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002410 · doc4.xml · derivative · entry 8 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,028 Underlying: Ordinary Shares · 14,513 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 02:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 65,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002410 · doc4.xml · derivative · entry 7 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 65,696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F5 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 02:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002410 · doc4.xml · derivative · entry 6 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,983 Underlying: Ordinary Shares · 17,983 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 02:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 134,698 | $73.28 | $9,870,669.44 |
DisclosureSEC source: 0001209191-21-002410 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,181 Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 02:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 205,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002410 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,879 F2 · kind: On January 5, 2018 and January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2020, the PSUs vested as to the number of shares reported above. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 02:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 98,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-002410 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 34,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002410 · doc4.xml · derivative · entry 5 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,928 Underlying: Ordinary Shares · 34,928 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 21:16 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 1,823 | $76.23 | $138,967.29 |
DisclosureSEC source: 0001209191-20-048263 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 102,925 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.18 to $76.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 21:16 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 27,753 | $75.73 | $2,101,734.69 |
DisclosureSEC source: 0001209191-20-048263 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 104,748 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.13 to $76.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:27 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 104,994 | $38.00 | $3,989,772.00 |
DisclosureSEC source: 0001209191-20-027690 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 132,501 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2020. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 11,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013971 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 237,495 Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 11,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013971 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The total number of directly owned shares held by the Reporting Person has been adjusted to correct a typographical error made on his Form 4 filed on February 21, 2020. F1 · balance_after: The total number of directly owned shares held by the Reporting Person has been adjusted to correct a typographical error made on his Form 4 filed on February 21, 2020. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 01:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 30,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011831 · doc4.xml · derivative · entry 5 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,014 Underlying: Ordinary Shares · 30,014 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. F1 · derivative.exercise_date: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. F1 · derivative.expiration_date: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 01:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 6,649 | $36.06 | $239,762.94 |
DisclosureSEC source: 0001209191-20-011831 · doc4.xml · nonDerivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,407 Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 01:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 15,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011831 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,056 F1 · kind: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. Read SEC document |
| February 14, 2020 Filed Feb 22, 2020 01:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 226,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011831 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 226,043 Read SEC document |
| February 14, 2020 Filed Feb 22, 2020 01:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 226,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011831 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,049 Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 21:17 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 11,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004651 · doc4.xml · derivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,114 Underlying: Ordinary Shares · 11,114 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F1 · derivative.exercise_date: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F1 · derivative.expiration_date: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 21:17 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,461 | $38.25 | $94,133.25 |
DisclosureSEC source: 0001209191-20-004651 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,137 Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 21:17 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 5,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004651 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,598 F1 · kind: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 23:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 65,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002340 · doc4.xml · derivative · entry 6 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,696 Underlying: Ordinary Shares · 65,696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F5 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 23:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002340 · doc4.xml · derivative · entry 5 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,966 Underlying: Ordinary Shares · 17,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 23:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 69,321 | $36.10 | $2,502,488.10 |
DisclosureSEC source: 0001209191-20-002340 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,043 Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 23:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 72,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002340 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,364 F2 · kind: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2020, the PSUs vested as to the number of shares reported above. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 23:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 83,678 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-002340 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 23:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 43,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002340 · doc4.xml · derivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,541 Underlying: Ordinary Shares · 43,541 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:42 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 10,000 | $28.00 | $280,000.00 |
DisclosureSEC source: 0001209191-19-053432 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2019. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:42 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 10,000 | $28.01 | $280,100.00 |
DisclosureSEC source: 0001209191-19-053432 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2019. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:41 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 1,359 | $28.00 | $38,052.00 |
DisclosureSEC source: 0001209191-19-048266 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2019. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,516 | $0.00 Strike: $22.14 | $0.00 |
DisclosureSEC source: 0001209191-19-047330 · doc4.xml · derivative · entry 6 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,484 Underlying: Ordinary Shares · 4,516 shares Expires 2025-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on the first anniversary of March 23, 2015 (the date of grant), and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Options (Right to Buy) · Derivative | 25,060 | $0.00 Strike: $15.96 | $0.00 |
DisclosureSEC source: 0001209191-19-047330 · doc4.xml · derivative · entry 5 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,940 Underlying: Ordinary Shares · 25,060 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on the first anniversary of June 27, 2014 (the date of grant), and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 4,516 | $22.14 | $99,984.24 |
DisclosureSEC source: 0001209191-19-047330 · doc4.xml · nonDerivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 25,060 | $15.96 | $399,957.60 |
DisclosureSEC source: 0001209191-19-047330 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 20:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 14,201 | $28.01 | $397,770.01 |
DisclosureSEC source: 0001209191-19-047330 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,093 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2019. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 20:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 56,702 | $28.00 | $1,587,656.00 |
DisclosureSEC source: 0001209191-19-047330 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,294 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2019. F2 · balance_after: Includes 2,370 ordinary shares of the Issuer acquired by the reporting person on May 31, 2019 pursuant to an employee stock purchase program. Read SEC document |
| March 23, 2019 Filed Mar 26, 2019 01:13 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021269 · doc4.xml · derivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 31,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 23, 2019 Filed Mar 26, 2019 01:13 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 13,733 | $26.84 | $368,593.72 |
DisclosureSEC source: 0001209191-19-021269 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,626 Read SEC document |
| March 23, 2019 Filed Mar 26, 2019 01:13 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 31,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021269 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 22:22 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 32,064 | $21.54 | $690,658.56 |
DisclosureSEC source: 0001209191-19-012696 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,359 Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 22:22 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 72,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-012696 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,423 F1 · kind: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met. F1 · shares: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.